SPORE in Lymphoma
Description: OVERALL NARRATIVE Cellular immunotherapy has enormous potential to improve the therapy of lymphoma. The SPORE research plan outlined in this renewal application seeks to develop more effective cellular immunotherapies by increasing their antitumor activity against lymphomas in children and adults, reducing treatment-related complications, and simplying therapies to use banked allogeneic products that are immediately available. Results of these studies will lay the foundation for future comparative trials and licensing investigations.
Funder: National Cancer Institute
Funding type: program
Funder scheme: P50
Start date: 2007-04-01
End date: 2027-08-31
Investigator: MALCOLM K. BRENNER
Institution: BAYLOR COLLEGE OF MEDICINE
Funded outputs count: 429
Funder award ID: P50CA126752
OpenAlex ID: G9000915301